ERBB2 and non-small cell lung carcinoma: Another example is the adaptive phase 2 umbrella study CTONG1702 investigating pyrotinib, an irreversible tyrosine kinase inhibitor against EGFR, HER2, and HER4, in treatment naive, advanced HER2-mutant NSCLC.